Summit Therapeutics Inc
SMMTHealthcare|Biotechnology|USA
$15.25
-0.23 (-1.49%)
Tangible Book
$0.70
Earnings Power
$1.03
Upcoming Data Readouts (23)
Sep 2026
Est. completion
P2TBI Traumatic Brain Injury
Veterans' Cognitive Function, Mental Health, and Quality of Life After Hyperbaric Oxygen Therapy
NCT07214415n=54
Dec 2026
Est. completion
Apr 2027
Est. completion
P2Endometrial Cancer
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
NCT06925724n=50
May 2027
Est. completion
NAPregnancy
A Study of Multiple Micronutrient Supplementation (MMS) to Increase Adherence With Digital Technology
NCT07555093n=10,012
Jun 2027
Est. completion
Aug 2027
Est. completion
P2Advanced Head and Neck Squamous Cell Carcinoma
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
NCT07094685n=28
Aug 2027
Est. completion
P2Biliary Tract Cancer
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
NCT06529718n=72
Sep 2027
Est. completion
P2Metastatic Esophageal Adenocarcinoma
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
NCT06846346n=88
Dec 2027
Est. completion
P2Extensive Stage Lung Small Cell Cancer
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
NCT07057791n=60
Dec 2027
Est. completion
P2TNBC
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
NCT07017673n=34
Jan 2028
Est. completion
P2Ivonescimab
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT06940518n=40
Jan 2028
Est. completion
Apr 2028
Est. completion
P1P2Non-Small Cell Lung Cancer
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
NCT07535437n=66
Apr 2028
Est. completion
P1P2Non-Small Cell Lung Cancer
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
NCT07535463n=53
Apr 2028
Est. completion
P3Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514n=780
May 2028
Est. completion
P3Metastatic Colorectal Cancer (CRC)
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832n=600
Jul 2028
Est. completion
P2Metastatic Colorectal Cancer
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
NCT06959550n=90
Sep 2028
Est. completion
P2Cutaneous Squamous Cell Carcinoma
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
NCT06567314n=24
Dec 2028
Est. completion
P3Non-Small Cell Lung Cancer
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608n=1,600
Apr 2029
Est. completion
Awaiting Results (5)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2025
A Retrospective, Multi-center Real-world Study of Steerable Ureteroscopic Renal Evacuation (SURE) Procedure With the CVAC® System
NCT07225933